CAR T/NK-CELLS FOR USE IN THE TREATMENT OF INVASIVE FUNGAL INFECTIONS

Current antifungal treatment effectiveness depends on drug selection and diagnosis. In this context, azoles, echinocandins and polyenes are the main antifungal agents used for invasive fungal infections (IFIs) treatment. More specifically, ergosterol and 1,3-β-glucan biosynthesis inhibitors, such as fluconazole and caspofungin, respectively, are used as first-line therapeutic agents. However, these compounds have multiple side effects including cross-resistance, toxicity and drug interactions. So, there is an unmet medical need of finding alternative antifungal therapies, which can be used to efficiently treat fungal infection without causing relevant side effects. The present invention is focused on solving this problem.